Publications & Patents


2005 Detection of an active substance for killing of murine fibrosarcoma tumor cells by releasing apoptosis effectors, comprises adding a catalase inhibitor and detecting catalase activity and apoptotis cells DE102005027796 (B4)

2017 Taste modulating flavoring substances WO2018233841 (A1)

Bicoll in the Press

Bicoll: The First Sino-German Biotechnology Company, Lamottke, C. Haug, N. Feling, Chapter: IV, The Experience of European Pharma Companies, in The Chemical and Pharmaceutical Industry in China – Opportunities and Threats for Foreign Companies, Festel, G.; Kreimeyer, A.; Oels, U.; Zedtwitz, M.v. (Hrsg.); Springer, 2005, ISBN: 3-540-22544-7

Declining Biodiversity – A Threat to Future Pharmaceutical Development, The Bulletin – Hong Kong Chamber of Commerce, Special Reports; Jan. 2006, pp. 48-52 Authors:Dr. Nicole Feling, Dr. Kai Lamottke

R&D takes off in Shanghai, C&EN Volume 84 Issue 34 | pp. 15-22 Issue Date: August 21, 2006

Ideales Umfeld – Für Rittal und Bicoll bleibt Shanghai der Drachenkopf, China Contact 9/2006, pp. 12-13

Biotechnologie made in China, GoingPublic, special edition “Biotechnologie 2005”, pp. 62-64

Heilung aus der Hexenküche, Berliner Tagesspiegel, 22.11.2006, page 28,

China Strides Toward Global Pharma Role, Chemical & Engineering News, Volume 85, Number 11, pp. 15-19

Shanghai Revisted, Chemical & Engineering News, Volume 85, Number 19, p. 5

Chinese plants for modern drug discovery campaigns, Chimica Oggi/CHEMISTRY TODAY, Volume 25, Number 5, Insert: Outsourcing from China Authors: Dr. Christian Haug, Dr. Nicole Feling, Dr. Kai Lamottke

Medikamentenentwicklung – Naturstoffe aus China, transkript, 14. Jahrgang, 6/2008, pp. 40-41 Authors: Dr. Kai Lamottke, Dr. Christian Haug, Dr. Nicole Feling

The right match – German SMEs: Challenges, Strategies and Success in a Competitive China, GC Ticker: bi-monthly newsletter of the German Chamber of Commerce, 4, 2010, p. 35

Publications by Bicoll

The roots of innovation – Can we afford to turn away from natural product drug discovery research?, European Biopharmaceutical Review, January 2011, p.52

Working in the Chinese Drug Industry, Chemical & Engineering News, 89(7), February 14, 2011

The Identification of Naturally Occurring Neoruscogenin as a Bioavailable, Potent and High-Affinity Agonist of the Nuclear Receptor RORa (NR1F1), S. Helleboid, C. Haug, K. Lamottke, Y. Zhou, J. Wei, S. Daix, L. Cambula, G. Rigou, D. W. Hum, R. Walczak, Journal of Biomolecular Screening, Jul 2013, DOI: 10.1177/1087057113497095.

Evaluation of the Anti-inflammatory and Anti-oxidative Potential of Four Fern Species from China Intended for Use as Food Supplements, C. Dion, C. Haug, H. Guan, C. Ripoll, P. Spiteller, A. Coussaert, E. Boulet, D. Schmidt, J. Wei, Y. Zhou, K. Lamottke, Natural product communications, 10(4), 597-603, April 2015.

Slow horses and hidden champions in the drug discovery field K. Lamottke, April 2015 DOI:10.13140/RG.2.1.4137.4242

MicroRNAs in epilepsy: pathophysiology and clinical utility, Prof. David C. Henshall, Prof. Hajo M. Hamer, MD, Prof. R. Jeroen Pasterkamp, PhD, Prof. David B. Goldstein, PhD, Prof. Jørgen Kjems, PhD, Prof. Jochen H. M. Prehn, PhD, Stephanie Schorge, PhD, Kai Lamottke, PhD, Felix Rosenow, MD, THE LANCET Neurology, Dec. 2016, DOI:

Public impulses to support biotechnology: Healthcare system in China, “Öffentlich getriebene Impulse zur Unterstützung der Biotechnologie”, M. Lamottke, Y. Zhou, “Das Gesundheitswesen in China” Medizinisch Wissentschaftliche Verlagsgesellschaft, 2017, Pp. 165-179 ISBN: 978-3-95466-303-3

“Half of the top 200 drugs in the world are inspired by plants”, Read more online or download Interview with

BICS01 Mediates Reversible Anti-seizure Effects in Brain Slice Models of Epilepsy, G. Morris, M. Heiland, K. Lamottke, H. Guan, T. D. M. Hill, Y. Zhou, Q. Zhu, S. Schorge, D. C. Henshall, Frontiers in Neurology, Jan. 2022, DOI: or download here

Join us at Biotech and Pharma Partnering, September 28-30Partnering
+ +